Dual Exhibitions Shine Bright | From CPHI Shanghai to the Tianjin Nucleic Acid Conference, Allbiosyn leverages technological innovation to connect the global nucleic acid therapeutics industry.
Release Date:2026-08-10
In the height of summer 2026, Allbiosyn Biotechnology Co., Ltd. is forging ahead at the forefront of the industry. From Shanghai’s Pudong district along the Huangpu River to Tianjin’s Binhai New Area by the Haihe River, Allbiosyn has made successive appearances at the 24th CPHI China and the 10th China (Tianjin) Nucleic Acid Drug Conference, proudly proclaiming itself a “global manufacturer” of nucleic acid raw materials and amplifying the powerful voice of China’s innovative capabilities in this field.

First Stop: CPHI Shanghai
June 16–18, 2026, Shanghai New International Expo Center, The 24th China International API Exhibition (CPHI China 2026) With an exhibition space of 250,000 square meters, more than 3,700 domestic and international exhibitors, and over 110,000 professional visitors, the event has once again set a new record for Asia’s pharmaceutical trade show. This year’s edition is themed “ Pooling strengths for collaborative innovation, ushering in the future of medicine. “With this theme, the event will comprehensively showcase the pharmaceutical industry’s transformation from an era of “scale competition” to one of “technological intensity.””

At the exhibition booth, in-depth discussions were held with customers from both China and abroad.



Breakthroughs in Key Raw Materials and Technologies
Allbiosyn showcased its core product portfolio at the CPHI exhibition, highlighting key raw materials and technological solutions that span the entire nucleic acid drug value chain.
The company’s proprietary core platforms—including novel polyphosphorylation technology, next-generation nucleic acid synthesis, RNA circularization and modification, selective delivery of nucleic acid therapeutics, enzyme‑catalyzed oligonucleotide synthesis, and liquid‑phase synthesis of small nucleic acids—have drawn significant attention from a broad audience of industry professionals, fully demonstrating the company’s end-to-end technological capabilities in the nucleic acid drug‑ingredient sector, spanning from R&D to commercialization.
Stop Two: Tianjin Nucleic Acid Drug Conference
From August 6 to 7, 2026, the event hosted by the China Biochemical Pharmaceutical Industry Association… The 10th China (Tianjin) Nucleic Acid Drug Conference It was solemnly held at the InterContinental Tianjin Yujiabao Hotel. This year’s conference is themed “ Breaking new ground in diverse nucleic acid technologies to jointly advance end-to-end translational applications. Under the theme, the event brings together academicians, industry leaders, and top experts from academia, industry, research, education, application, management, and investment—spanning the entire value chain—and features a plenary session with forward-looking keynote addresses, alongside four parallel sub‑sessions, all focused on cutting-edge core technologies such as small nucleic acids and mRNA.




The 2026 dual exhibitions concluded successfully.
Looking ahead, the company will remain committed to its mission of becoming a premier supplier of nucleoside and nucleotide raw materials in the fields of nucleic acid therapeutics, DNA/RNA synthesis, and mRNA vaccines, advancing with even greater resolve into a new phase of growth.
On the R&D front, we continue to ramp up investment, focus on breakthroughs in key core technologies, and steadily enhance product quality while strengthening our technological moats.
On the market front, we will focus on deepening our global footprint, accelerating the development of overseas distribution channels and enhancing our localized operational capabilities, with the aim of securing a more central position in the global nucleic acid raw-material supply chain.
Recent News
In the height of summer 2026, Allbiosyn Biotechnology Co., Ltd. is forging ahead at the forefront of the industry.
Allbiosyn Debuts at CPHI Shanghai 2025
Allbiosyn made its exhibition debut at CPHI Shanghai 2025, presenting novel nucleic acid raw materials including high-purity modified nucleosides, phosphoramidites, and customized nucleotide modifiers.
Allbiosyn Showcases Innovative Nucleic Acid Solutions at CPHI Shenzhen 2025
Allbiosyn recently exhibited at CPHI Shenzhen, strengthening its presence as a leading provider of nucleic acid raw materials and synthesis technologies. The event provided an ideal platform to connect with key players in the pharmaceutical and biotech industries.
On March 15, 2025, the three-day 2025 E-Trade Bio-industry Conference (BIOCHINA) successfully concluded at Suzhou International Expo Center. This conference, themed "Innovation Without Borders, Collaborative Coexistence," gathered 850 top global speakers and 30,000 professional attendees, covering 50,000㎡ of exhibition space, comprehensively showcasing cutting-edge technologies and industrial potential in the biomedical field. As a leader in the nucleic acid raw material sector, Allbiosyn Bio showcased its core product matrix at the exhibition, to jointly explore the future of nucleic acid drug industrialization with global partners.
Wish to receive more updates from Allbiosyn
Stay up-to-date with the latest product releases, technology trends, and upcoming events.
- All
- Product Management
- News Information
- Introduction Content
- Enterprise Outlets
- FAQ
- Corporate Video
- Corporate Album
Phone: +8618666985712
Email: info@allbiosyn.com
WeChat ID: 18666985712
Add: Room 502, 5th Floor, Building 11, No. 288 Huifeng North Road, Fengxian District, Shanghai, China
Copyright © 2025 Allbiosyn Biotechnology Co., Ltd. All Rights Reserved.